Verastem, Inc.
0LOV.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$676.63M
Close$
Share Statistics
| Market cap | $676.63 Million |
|---|---|
| Enterprise Value | $616.66 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -405.51% |
|---|---|
| Return on Assets | -98.15% |
| Return on Invested Capital | -124.47% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7.05 |
| Enterprise Value to EBIT | -3.86 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 1.53 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Verastem Inc
102 employees
CEO: Brian Stuglik Verastem, Inc. is an emerging biopharmaceutical firm dedicated to the discovery, development, and eventual commercialization of innovative therapies targeting various cancers. Central to its pipeline is VS-6766, an investigational compou...